ES2144792T3 - Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis. - Google Patents

Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.

Info

Publication number
ES2144792T3
ES2144792T3 ES96940912T ES96940912T ES2144792T3 ES 2144792 T3 ES2144792 T3 ES 2144792T3 ES 96940912 T ES96940912 T ES 96940912T ES 96940912 T ES96940912 T ES 96940912T ES 2144792 T3 ES2144792 T3 ES 2144792T3
Authority
ES
Spain
Prior art keywords
atherosclerosis
medication
prevention
preparation
nadph oxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940912T
Other languages
English (en)
Inventor
James A Holland
David K Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Application granted granted Critical
Publication of ES2144792T3 publication Critical patent/ES2144792T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PROPORCIONA UN METODO PARA LA PREVENCION Y EL TRATAMIENTO DE LA ATEROSCLEROSIS Y ENFERMEDADES RELACIONADAS EN MAMIFEROS, EN EL QUE SE ADMINISTRA UN INHIBIDOR DE LA NADPH OXIDASA. EL INHIBIDOR DE LA NADPH OXIDASA PREVIENE LA PRODUCCION DE ESPECIES DE OXIGENO REACTIVO ANTE LA EXPOSICION DE LAS CELULAS ENDOTELIALES A NIVELES ATEROGENICOS DE LDL, DANDO LUGAR ASI A UNA DISMINUCION DE LA ENDOCITOSIS Y LA HIPERPERMEABILIDAD VASCULAR. LOS INHIBIDORES PREFERIDOS DE LA NADPH OXIDASA SON LOS CORRESPONDIENTES A LA FORMULA (I). ADEMAS, SE PROPORCIONA UN METODO DIAGNOSTICO PARA PREDECIR EL RIESGO DE ENFERMEDADES ATEROSCLEROTICAS PARA UN PACIENTE HUMANO.
ES96940912T 1995-11-27 1996-11-27 Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis. Expired - Lifetime ES2144792T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/562,767 US5763496A (en) 1995-11-27 1995-11-27 Prevention of atherosclerosis using NADPH oxidase inhibitors

Publications (1)

Publication Number Publication Date
ES2144792T3 true ES2144792T3 (es) 2000-06-16

Family

ID=24247689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940912T Expired - Lifetime ES2144792T3 (es) 1995-11-27 1996-11-27 Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.

Country Status (10)

Country Link
US (2) US5763496A (es)
EP (2) EP0861070B1 (es)
JP (2) JPH11507946A (es)
AT (1) ATE189957T1 (es)
AU (1) AU1085997A (es)
CA (1) CA2238098C (es)
DE (1) DE69606882T2 (es)
ES (1) ES2144792T3 (es)
GR (1) GR3033067T3 (es)
WO (1) WO1997019679A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9226198A (en) * 1997-09-10 1999-03-29 Johns Hopkins University School Of Medicine, The The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
NZ509803A (en) * 2000-02-09 2001-08-31 Paul A Treatment of fibromyalgia with ubiquinone 10 and succinic acid
WO2001089517A2 (en) * 2000-05-19 2001-11-29 Thomas Jefferson University Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
WO2002030453A1 (en) * 2000-10-12 2002-04-18 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
DE10104825A1 (de) * 2001-02-01 2002-08-08 Florian Lang Screening von Antimalariamitteln
AU2002353996A1 (en) * 2001-11-01 2003-05-12 Rensselaer Polytechnic Institute Solid-phase array-based biocatalytic transformations
AU2002359790A1 (en) * 2001-12-21 2003-07-15 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
AU2003224549A1 (en) * 2002-04-17 2003-10-27 Biovitrum Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
AU2003233147B2 (en) * 2002-05-13 2008-03-06 Arexis Ab Autoimmune conditions and NADPH oxidase defects
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
US20070037739A1 (en) * 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
AU2004216541A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
TW200509886A (en) * 2003-05-02 2005-03-16 Takara Bio Inc Therapeutic agent
WO2005103297A1 (en) * 2004-03-31 2005-11-03 Georgetown University METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
KR100989093B1 (ko) * 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
US20140080850A1 (en) * 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
CA2912302A1 (en) 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11938117B2 (en) 2016-09-01 2024-03-26 Nutrition21, LLC Magnesium biotinate compositions and methods of use
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
DE4109627A1 (de) * 1991-03-23 1992-09-24 Boehringer Mannheim Gmbh Neue phenolether, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
JPH06135880A (ja) * 1992-10-30 1994-05-17 Kanebo Ltd 活性酸素消去剤
JP3023254B2 (ja) * 1992-11-05 2000-03-21 鐘紡株式会社 メラニン生成抑制剤
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
JPH07165575A (ja) * 1993-12-08 1995-06-27 Nippon Oil & Fats Co Ltd ヒドロキノン誘導体
JP2774063B2 (ja) * 1993-12-24 1998-07-09 鐘紡株式会社 抗酸化組成物

Also Published As

Publication number Publication date
WO1997019679A3 (en) 1997-08-28
US5902831A (en) 1999-05-11
CA2238098C (en) 2001-01-30
EP0914821A3 (en) 2000-04-26
CA2238098A1 (en) 1997-06-05
AU1085997A (en) 1997-06-19
DE69606882D1 (de) 2000-04-06
US5763496A (en) 1998-06-09
GR3033067T3 (en) 2000-08-31
EP0861070A2 (en) 1998-09-02
WO1997019679A2 (en) 1997-06-05
DE69606882T2 (de) 2000-08-17
EP0914821A2 (en) 1999-05-12
ATE189957T1 (de) 2000-03-15
EP0861070B1 (en) 2000-03-01
JPH11507946A (ja) 1999-07-13
JP2003176224A (ja) 2003-06-24

Similar Documents

Publication Publication Date Title
ES2144792T3 (es) Uso de inhibidores de la nadph oxidasa para la preparacion de un medicamento para la prevencion de la aterosclerosis.
FI872756A (fi) Med laserstraolning fungerande terapeutisk anordning.
DZ2375A1 (fr) Prévention de la perte et restauration de la masseosseuse par certains agonistes des prostaglandine s.
DE69619448D1 (de) Blutdruckmessgerät
DE68903516D1 (de) Mittel zur senkung des blutdrucks.
KR970000401U (ko) 채혈용 란셋
AU4594796A (en) System and method for diagnosis of living tissue diseases
IT8567350A1 (it) Dispositivo per la fabbricazione di corpi assorbenti, particolarmente per la fabbricazione di assorbenti igienici e simili.
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
NO975319D0 (no) System for måling av oksygennivå i blod
ES2110414T3 (es) Derivados de sacarina utiles como inhibidores de enzimas proteoliticas y su preparacion.
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
AU8439998A (en) Compounds
ES2176778T3 (es) Metodo de diagnostico para la aterosclerosis.
NO963108L (no) Substituerte kanelsyreguanidider, fremgangsmåte for fremstilling, anvendelse som medikament eller diagnostikum som inneholder disse
EP0758021A3 (en) Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof
DE69620088D1 (de) Blutdruckmessgerät
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
AU2909495A (en) Evaluation of blood coagulation activity
DE69405284D1 (de) Manschette für Blutdruckmesser
ES2179867T3 (es) Entrecruzamientos de piridinolina como marcadores de actividad de enfermedad periodontal o peri-implante.
FI861093A0 (fi) Bioelektrisk patientmonitor.
NO980564D0 (no) Sulfonamid-substituerte forbindelser, fremgangsmåte for fremstilling, anvendelse som medikament eller diagnostikum samt oppnådd medikament er beskrevet
DE69013139D1 (de) Mittel zur Vorbeugung, Diagnose und Therapie von rheumatischen, autoimmunen, Haut- und Bindegewebekrankheiten von unbekannter Aetiologie und Verfahren zu seiner Herstellung und Verwendung.
ES1032126Y (es) Juego esterilizable para la autoinyeccion de drogas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 861070

Country of ref document: ES